Compare AbCellera Biologics Inc (ABCL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Health Care Select Sector SPDR Fund — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Health Care Select Sector SPDR Fund trades at $163.15. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | XLV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $164.48 |
52-Week Low | $2.78 | $129.01 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
XLV trades at $162.06, down 1.03% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The healthcare ETF benefits from defensive sector positioning amid market volatility, with recent news highlighting healthcare as a safe haven during choppy markets. A dividend of $0.66 is scheduled for June 2026, providing income appeal.
Outlook remains positive given healthcare's defensive characteristics and innovation momentum in biotech and pharmaceuticals. Key risks include sector-specific regulatory pressures and patent cliff concerns for major holdings. Analyst sentiment leans bullish with technical support at $160 and resistance at $164.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
